Cuba will hold the International Congress of Biotechnology in April

Havana, Jan 9 (Prensa Latina) The Group of the Biotechnology and Pharmaceutical Industry of Cuba (BioCubaFarma), summoned the world scientific community to the BioHabana International Congress.

According to a statement from this entity, the appointment scheduled to be held from April 25 to 29, as its main objective to carry out a translation exercise of Life Sciences in Business Development, in a new scientific context, management of innovation, and global health.

The meeting, which will take place in the Convention Center of the Caribbean capital, will allow a broad debate of the experiences and results of the participants, coming from both industrialized and developing countries, for the construction of alliances that allow a greater impact on public health.

Cuba is a small country with scarce material resources, but with notable results in controlling the disease, highlighted the BioCubaFarma statement while warning about the need to face in the future and jointly the increase in the burden of mortality from chronic noncommunicable diseases in the world.

Among the main themes of the event will be the Covid-19 pandemic, medical technology and industry 4.0; as well as chronic inflammation, cancer, and autoimmunity; agricultural biotechnology and brain diseases.

They will also address subjects such as bioprocesses and innovation in new business models for high-tech sectors.

The biological sciences, the text affirms, are going through a stage of fundamental changes, similar to those that occurred in physics at the beginning of the 20th century and the main engine of these changes is in the convergence with other sciences.

In this context, he indicates, the «global» nature of the challenges to human health (as illustrated by the Covid-19 pandemic), as well as the food, energy and environmental challenges, is increasingly evident.

It also refers to the fact that the confrontation with the pandemic has revealed the response capacity of the scientific community and the biopharmaceutical industry, based on a multidisciplinary and inter-institutional approach that has achieved an unprecedented integration in the history of Biomedical Sciences.

«It is time to take advantage of the momentum generated in the last two years to face the post-Covid-19 stage,» he emphasizes.